minimum number of subject in bioequivalence study [Power / Sample Size]

posted by ElMaestro  – Denmark, 2014-09-27 13:26 (3866 d 08:46 ago) – Posting: # 13601
Views: 18,042

Hello Khaoula,

❝ – Why the minimum simple size fixed by all regulatory authorities is 12? because when we consult the table of Sample Size for Schuirmann’s Two One-Sided t-Tests Procedure, we note that for low CV <15% the number of subject required is <12?


You're right you might get good level of power for N<12 but regulators have decided to set a limit and they set that limit at 12. Not sure there is a really good reason, but that's just the way it is.

❝ – in pilot study, we need small simple size, but could it be greater than 12?


Pick any number you like. But be aware that the value of a pilot study tends to be limited if you have few subjects. In this regard it is impossible to tell what "few" really means - that would depend on the actual GMR, its CV and the purpose of the pilot. Therefore, I'd say use as many subjects in the pilot as you can within the meaning of ethics and budgets and everything else.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
89 visitors (0 registered, 89 guests [including 2 identified bots]).
Forum time: 22:12 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5